Agreement with Guidelines from a Large Database for Management of Systemic Sclerosis: Results from the Canadian Scleroderma Research Group

Journal of Rheumatology

Volumn 39, Issue 3, 2012, Pages 524-531

  Pope, Janet ^a   Harding, Sarah ^a   Khimdas, Sarit ^a   Bonner, Ashley ^b   Hudson, M ^d   Markland, J ^d   Docherty, P ^d   Fritzler, M ^e   Jones, N ^d   Kaminska, E ^d   Khalidi, N ^d   Ligier, S ^d   Masetto, A ^d   Mathieu, J P ^d   Robinson, D ^d   Smith, D ^d   Sutton, E ^d   Baron, Murray ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Advanced Diagnostics Laboratory ^*

^e Advanced Diagnostics Laboratory   (Canada)

Author keywords

Canadian Scleroderma Research Group adherence; Eular; Eustar; Guidelines; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; ILOPROST; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; PROSTACYCLIN; PROTON PUMP INHIBITOR; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ADULT; ARTHRITIS; ARTICLE; BLOATING; DIGITAL ULCER; DRUG USE; DYSPHAGIA; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL REFLUX; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; MYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCREENING; SYSTEMIC SCLEROSIS; ULCER;

ADULT; AGED; CANADA; DATABASES, FACTUAL; DISEASE MANAGEMENT; EUROPE; FEMALE; GASTROINTESTINAL DISEASES; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84863279830     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110121     Document Type: Article

References (19)

1. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis. J Rheumatol 2002;29:1867-73. (Pubitemid 34988694)
2. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. Outcome measurements in scleroderma: Results from a delphi exercise. J Rheumatol 2007;34:501-9. (Pubitemid 46364004)
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
4. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002;138:99-105. (Pubitemid 34056240)
5. Silver RM. Clinical aspects of systemic sclerosis (scleroderma). Ann Rheum Dis 1991;50 Suppl 4:854-61.
6. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203. (Pubitemid 29268956)
7. Leighton C. Drug treatment of scleroderma. Drugs 2001;61:419-27. (Pubitemid 32270048)
8. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8. (Pubitemid 32537533)
9. Pope JE. Connective tissue diseases: New evidence-based guidelines for treating SSc. Nat Rev Rheumatol 2009;5:300-2.
10. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009;60:1831-9.
11. Pope JE, Ouimet JM, Krizova A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006;55:138-45. (Pubitemid 43235139)
12. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
13. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
14. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - A retrospective analysis. Rheumatology 2007;46:442-5. (Pubitemid 46344656)
15. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006;45:1005-8. (Pubitemid 44283057)
16. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005;32:1273-8. (Pubitemid 40995382)
17. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: Comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65. (Pubitemid 351374421)
18. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006;36 Suppl 3:10-5. (Pubitemid 44179776)
19. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005;16:2168-74. (Pubitemid 41790940)